Sartorius (SRT3) Stock Overview

Provides bioprocess solutions, and lab products and services worldwide. More details

SRT3 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	4/6
Past Performance	4/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 35.6% below our estimate of its fair value

Earnings are forecast to grow 20.69% per year

Earnings grew by 70.1% over the past year

Analysts in good agreement that stock price will rise by 29%

Risk Analysis

Has a high level of debt

SRT3 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Sartorius Aktiengesellschaft Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sartorius
Historical stock prices
Current Share Price	€191.85
52 Week High	€213.20
52 Week Low	€213.20
Beta	1.4
1 Month Change	-11.18%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	-46.62%
Change since IPO	652.35%

Recent updates

Shareholder Returns

	SRT3	CH Life Sciences	CH Market
7D	-4.9%	-3.2%	0.3%
1Y	n/a	-12.9%	6.1%

Return vs Industry: Insufficient data to determine how SRT3 performed against the Swiss Life Sciences industry.

Return vs Market: Insufficient data to determine how SRT3 performed against the Swiss Market.

Price Volatility

Is SRT3's price volatile compared to industry and market?
SRT3 volatility
SRT3 Average Weekly Movement	4.4%
Life Sciences Industry Average Movement	6.0%
Market Average Movement	4.6%
10% most volatile stocks in CH Market	8.1%
10% least volatile stocks in CH Market	2.5%

Stable Share Price: SRT3 has not had significant price volatility in the past 3 months compared to the Swiss market.

Volatility Over Time: Insufficient data to determine SRT3's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1870	14,242	Michael Grosse	www.sartorius.com

Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell culture solutions, including bioreactors and fermenters, cell culture reagents, supplements and matrices, nucleic acid and delivery solutions, cell culture media, and cell lines and buffers; and fluid management products. It also provides lab filtration and purification solutions, lab water purification systems, microtissue technologies, lab weighing, pipettes, tips and dispensers, microbiological testing solutions, lab data and fleet management software, and OEM solutions; and Process chromatography and filtration solutions.

Sartorius Aktiengesellschaft Fundamentals Summary

How do Sartorius's earnings and revenue compare to its market cap?
SRT3 fundamental statistics
Market cap	CHF 11.68b
Earnings (TTM)	CHF 148.65m
Revenue (TTM)	CHF 3.25b

87.0x

P/E Ratio

4.0x

P/S Ratio

Is SRT3 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SRT3 income statement (TTM)
Revenue	€3.55b
Cost of Revenue	€1.93b
Gross Profit	€1.62b
Other Expenses	€1.46b
Earnings	€162.60m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Jul 23, 2026

Earnings per share (EPS)	2.36
Gross Margin	45.59%
Net Profit Margin	4.57%
Debt/Equity Ratio	105.3%

How did SRT3 perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

33%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/17 22:02
End of Day Share Price	2026/05/15 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sartorius Aktiengesellschaft is covered by 38 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Charles Pitman	Barclays
Charles Pitman	Barclays
Harry Gillis	Berenberg

Sartorius AktiengesellschaftSWX:SRT3 Stock Report